|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NET1 |
Gene summary for NET1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NET1 | Gene ID | 10276 |
| Gene name | neuroepithelial cell transforming 1 | |
| Gene Alias | ARHGEF8 | |
| Cytomap | 10p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | Q5SQI5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10276 | NET1 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.98e-02 | 4.19e-01 | -0.1088 |
| 10276 | NET1 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.80e-06 | 4.27e-01 | -0.1954 |
| 10276 | NET1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 9.84e-03 | 4.40e-01 | 0.281 |
| 10276 | NET1 | A015-C-203 | Human | Colorectum | FAP | 7.33e-11 | -8.05e-02 | -0.1294 |
| 10276 | NET1 | A001-C-108 | Human | Colorectum | FAP | 2.89e-05 | -1.21e-01 | -0.0272 |
| 10276 | NET1 | A002-C-205 | Human | Colorectum | FAP | 1.05e-06 | -1.67e-01 | -0.1236 |
| 10276 | NET1 | A015-C-006 | Human | Colorectum | FAP | 2.78e-05 | -2.22e-01 | -0.0994 |
| 10276 | NET1 | A015-C-106 | Human | Colorectum | FAP | 7.08e-06 | -1.05e-01 | -0.0511 |
| 10276 | NET1 | A002-C-114 | Human | Colorectum | FAP | 4.73e-06 | -2.71e-01 | -0.1561 |
| 10276 | NET1 | A015-C-104 | Human | Colorectum | FAP | 8.20e-14 | -1.98e-01 | -0.1899 |
| 10276 | NET1 | A001-C-014 | Human | Colorectum | FAP | 9.93e-05 | -1.02e-01 | 0.0135 |
| 10276 | NET1 | A002-C-016 | Human | Colorectum | FAP | 6.89e-06 | -1.49e-01 | 0.0521 |
| 10276 | NET1 | A015-C-002 | Human | Colorectum | FAP | 2.44e-02 | -2.21e-01 | -0.0763 |
| 10276 | NET1 | A001-C-203 | Human | Colorectum | FAP | 1.77e-05 | -8.66e-02 | -0.0481 |
| 10276 | NET1 | A002-C-116 | Human | Colorectum | FAP | 5.91e-14 | -1.57e-01 | -0.0452 |
| 10276 | NET1 | A014-C-008 | Human | Colorectum | FAP | 5.39e-04 | -2.59e-01 | -0.191 |
| 10276 | NET1 | A018-E-020 | Human | Colorectum | FAP | 2.87e-05 | -1.45e-02 | -0.2034 |
| 10276 | NET1 | F034 | Human | Colorectum | FAP | 4.34e-11 | -2.64e-01 | -0.0665 |
| 10276 | NET1 | CRC-3-11773 | Human | Colorectum | CRC | 5.18e-05 | -1.83e-01 | 0.2564 |
| 10276 | NET1 | LZE4T | Human | Esophagus | ESCC | 4.83e-05 | 6.08e-01 | 0.0811 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000030228 | Skin | cSCC | response to reactive oxygen species | 97/4864 | 222/18723 | 6.88e-09 | 2.25e-07 | 97 |
| GO:003459928 | Skin | cSCC | cellular response to oxidative stress | 117/4864 | 288/18723 | 3.37e-08 | 8.95e-07 | 117 |
| GO:004254227 | Skin | cSCC | response to hydrogen peroxide | 68/4864 | 146/18723 | 6.10e-08 | 1.56e-06 | 68 |
| GO:000726523 | Skin | cSCC | Ras protein signal transduction | 132/4864 | 337/18723 | 6.17e-08 | 1.57e-06 | 132 |
| GO:007147925 | Skin | cSCC | cellular response to ionizing radiation | 39/4864 | 72/18723 | 3.30e-07 | 6.62e-06 | 39 |
| GO:000931424 | Skin | cSCC | response to radiation | 166/4864 | 456/18723 | 4.37e-07 | 8.41e-06 | 166 |
| GO:001604925 | Skin | cSCC | cell growth | 173/4864 | 482/18723 | 7.21e-07 | 1.34e-05 | 173 |
| GO:001021225 | Skin | cSCC | response to ionizing radiation | 64/4864 | 148/18723 | 3.64e-06 | 5.50e-05 | 64 |
| GO:0034614111 | Skin | cSCC | cellular response to reactive oxygen species | 63/4864 | 155/18723 | 4.50e-05 | 4.72e-04 | 63 |
| GO:000155824 | Skin | cSCC | regulation of cell growth | 140/4864 | 414/18723 | 2.07e-04 | 1.72e-03 | 140 |
| GO:00703019 | Skin | cSCC | cellular response to hydrogen peroxide | 40/4864 | 98/18723 | 9.33e-04 | 6.38e-03 | 40 |
| GO:000726617 | Skin | cSCC | Rho protein signal transduction | 51/4864 | 137/18723 | 2.38e-03 | 1.38e-02 | 51 |
| GO:000697930 | Thyroid | HT | response to oxidative stress | 81/1272 | 446/18723 | 2.53e-16 | 1.17e-13 | 81 |
| GO:000030229 | Thyroid | HT | response to reactive oxygen species | 47/1272 | 222/18723 | 1.97e-12 | 4.05e-10 | 47 |
| GO:004254228 | Thyroid | HT | response to hydrogen peroxide | 32/1272 | 146/18723 | 2.66e-09 | 2.64e-07 | 32 |
| GO:006219730 | Thyroid | HT | cellular response to chemical stress | 54/1272 | 337/18723 | 3.07e-09 | 2.89e-07 | 54 |
| GO:003459929 | Thyroid | HT | cellular response to oxidative stress | 46/1272 | 288/18723 | 4.97e-08 | 3.15e-06 | 46 |
| GO:001604926 | Thyroid | HT | cell growth | 58/1272 | 482/18723 | 1.56e-05 | 3.82e-04 | 58 |
| GO:003461426 | Thyroid | HT | cellular response to reactive oxygen species | 25/1272 | 155/18723 | 4.60e-05 | 9.28e-04 | 25 |
| GO:007147926 | Thyroid | HT | cellular response to ionizing radiation | 15/1272 | 72/18723 | 8.17e-05 | 1.41e-03 | 15 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NET1 | SNV | Missense_Mutation | novel | c.500N>T | p.Ser167Phe | p.S167F | Q7Z628 | protein_coding | deleterious(0.03) | benign(0.396) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| NET1 | SNV | Missense_Mutation | c.727N>A | p.Asp243Asn | p.D243N | Q7Z628 | protein_coding | tolerated(0.09) | benign(0.015) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| NET1 | SNV | Missense_Mutation | rs773238555 | c.1081G>A | p.Glu361Lys | p.E361K | Q7Z628 | protein_coding | tolerated(0.19) | benign(0.075) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NET1 | SNV | Missense_Mutation | c.199N>G | p.Arg67Gly | p.R67G | Q7Z628 | protein_coding | deleterious(0) | possibly_damaging(0.528) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| NET1 | SNV | Missense_Mutation | c.296N>T | p.Thr99Met | p.T99M | Q7Z628 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NET1 | SNV | Missense_Mutation | c.272G>C | p.Arg91Thr | p.R91T | Q7Z628 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-LP-A4AX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NET1 | SNV | Missense_Mutation | c.449G>C | p.Arg150Thr | p.R150T | Q7Z628 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NET1 | SNV | Missense_Mutation | c.868N>A | p.Leu290Ile | p.L290I | Q7Z628 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NET1 | SNV | Missense_Mutation | c.1038N>G | p.Ile346Met | p.I346M | Q7Z628 | protein_coding | deleterious(0.01) | possibly_damaging(0.487) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | |
| NET1 | SNV | Missense_Mutation | c.1019N>G | p.Glu340Gly | p.E340G | Q7Z628 | protein_coding | deleterious(0.04) | benign(0.073) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |